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Chronic pruritus is a complex multifactorial symptom associated with many different diseases that
represents a diagnostic and therapeutic challenge for physicians. In order to better manage chronic
pruritus, a detailed medical history, individualized diagnostic procedures and treatment approaches are
necessary. Treatment should not only take itch into consideration, but also scratching-induced skin le-
sions and accompanying disorders such as anxiety, depression and insomnia. Various standardized
questionnaires and scales have been developed to assist in the characterization and assessment of these
parameters. Monodimensional scales (e.g. the visual analogue scale) represent a simple method for
assessing pruritus intensity and are frequently used; however, they can easily be confounded and may
indicate the level of satisfaction regarding the medical care provided rather than the itch course. The
Dynamic Pruritus Score and Itch-Free Days questionnaire enable a closer assessment of patient responses
to treatment. Because chronic pruritus has the potential to greatly impact the quality of life, it is
important that physicians recognize it as a major issue. The Dermatology Quality of Life Index is an
instrument that is used in a variety of dermatological conditions, but may be unsuitable for measuring
pruritus of extracutaneous origin. The ItchyQol is a tool designed speciﬁcally for those suffering from
pruritus. Additional tools, such as the Hospital Anxiety and Depression Scale, take psychiatric comor-
bidities into consideration. Recommendations from European (EADV-based Task Force Pruritus) and
international (International Forum for the Study of Itch) expert groups focusing on assessment in-
struments for chronic pruritus are also provided in this article.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Pruritus is the most common symptom in dermatology with
estimates showing that more than one-third of the patients
attending dermatological practices suffer from this symptom, a
majority of those chronically.1 The Global Burden of Disease project
listed pruritus as one of the 50 most common interdisciplinary
symptoms leading to high burden levels.2 Chronic pruritus, i.e.
pruritus lasting longer than 6 weeks, affects almost one ﬁfth of the
general population leading to great impairment of quality of life.3 It
should be thoroughly investigated, since not only dermatological
conditions cause chronic itch, but also systemic, neurologic orS. St€ander).
ety of Allergology.
rgology. Production and hosting by Elsepsychiatric diseases. Furthermore, different diseases may be pre-
sent simultaneously or, in some instances, the cause may remain
unknown.4
Since pruritus is a subjective symptom of multifactorial nature,
its assessment may be challenging.5 The International Forum for
the Study of Itch (IFSI) established a classiﬁcation system dividing
chronic pruritus into one of three categories upon physical exam-
ination: i) chronic pruritus on inﬂamed skin; ii) chronic pruritus on
normal skin and iii) chronic pruritus with severe scratch lesions.4
This classiﬁcation helps the attending physician to direct the
diagnostic efforts in order to determine the underlying cause. Many
factors, such as location, duration of the disease, intensity and
accompanying sensory symptoms (e.g. burning, tingling or stinging
sensations), should be taken into account. Moreover psychiatric
comorbidities (e.g. depression and anxiety), current mood or stress
levels may affect the pruritus perception and appraisal and thereby
confound the assessment of the symptom. In order to enable avier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Numerical rating scale.
Fig. 2. Visual analogue scale.
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founders, multiple instruments are recommended in the assess-
ment of chronic pruritus.5
Only a minority of patients suffering from chronic pruritus has
access to specialized centers. As a result the underlying causes are
often not comprehensively investigated and patients may receive
sub-standard care. Additionally treatment costs may be high and
some of the available therapy options are not covered by national
health systems or by health insurances. A higher awareness of the
societal burden is thus necessary in order to achieve a better
standardized care. Measuring itch is essential not only for the
proper care of the individual patients but also to raise awareness of
the relevance of chronic pruritus in health care. Furthermore, in
randomized clinical trials (RCT) measurement of pruritus should be
performed in a standardized manner to allow comparisons be-
tween studies and ensure the highest medical and professional
standards.
This review article aims to give an overview of the available
instruments for the measurement of itch (Table 1) and to give
recommendations for their use in patient care and in RCTs.
Pruritus intensity
An assortment of scales has been developed in order to better
assist physicians in assessing pruritus intensity. The intensity can
be quickly measured with monodimensional scales that are
routinely used in clinical care and RCTs. Patients can be asked to
rate their itch intensity from 0 (“no itch”) to 10 (“worst imaginable
itch”) with the numerical rating scale (NRS; Fig. 1). Another mon-
odimensional scale, the visual analogue scale (VAS), provides pa-
tients with the opportunity to indicate the intensity of their itch by
marking on a 10 cm long, ruler-shaped scale. Both endpoints are
marked with a number corresponding to the intensity, with 0 rep-
resenting “no itch” and 10 the “worst imaginable itch” (Fig. 2). A
variation of this scale demonstrates to patients that at one-third of
the length corresponding to 3.3 cm, they would normally feel the
urge to scratch. However, this biases the patient and should not be
used in RCTs. Scores below 3.0 VAS/NRS points are generallyTable 1
Overview of tools used for measuring pruritus.
Tool
Intensity Monodimensional:
 Visual analogue scale
 Numerical rating scale
 Verbal rating scale
Multidimensional:
 Itch Severity Scale
 Pruritus Grading System
Scratch lesions  Scratch Symptom Score
 Prurigo Activity Scale
Scratching activity  Actigraphy
 Accelerometer
Course of pruritus  Dynamic Pruritus Score
 Itch-Free Days
 5-D Scale
 Patient Beneﬁt Index
 ItchApp®
Psychiatric comorbidities  Hospital Anxiety and Depression Scale
 Beck Depression Inventory
 Hamilton Rating Scale for Depression
Sleep impairment  Stanford Sleepiness Scale
 Epworth Sleepiness Scale
 Athens Insomnia Scale
Quality of life  ItchyQol
 Dermatological Life Quality Index
 36-item short formassociated with mild itch, whereas scores higher than 6.9 illustrate
severe itch. Scores above 9.0 represent a very severe itch.6 The
verbal rating scale (VRS) is a further monodimensional scale that
allows patients to describe their itch intensity by means of gradu-
ally rising adjectives (0 e no itch, 4 e worst imaginable itch).7 The
NRS, VAS and VRS have been validated in large-scale studies con-
sisting of chronic pruritus patients with pruritic dermatoses or
pruritus of various origins. These instruments have high repro-
ducibility and there was a high correlation between scales.6e8
There is still no consensus on the best recall period (12 h, 24 h, 3
or 7 days). In RCTs it is common to address the past 24 h. However,
these scales only provide the itch intensity at a speciﬁc point in
time, being susceptible to cofounders such as current mood, stress
and comorbidities. Multidimensional scales, such as the Itch
Severity Scale,9 a self-reported seven-item scale, can be alterna-
tively used but are not routinely established in clinical care. They
combine itch intensity, sleep disturbance and burden by the
symptom aiming to give a comprehensive rating of the itch impact.
However, patients may face difﬁculties in unequivocal selection of a
category. Thus, these instruments are not recommended to be used
in RCTs until more research describes their validity in chronic
pruritus assessment.Scratch lesions and scratching activity
Scratch lesions may be an indirect sign indicating the severity of
a pruritic condition (Fig. 3). The Scratch Symptom Score (SSS) and
the Prurigo Activity Score are descriptive tools that have been
constructed for use in monitoring scratch lesions over time.10
However, they are not validated yet limiting their use in RCTs.
Alternatively, wrist actigraphy, a non-invasive method of moni-
toring motor activity, can be utilized to assess scratching behavior
in humans.11,12 Accelerometers are devices that measure proper
acceleration and can be used for similar purposes. Both methods of
objectively measuring scratch activity are mainly used for research
purposes or RCTs but not in daily practice. However, scratch lesions
and scratching activity do not necessarily demonstrate the severity
of the pruritus. To prevent the development of lesions, some pa-
tients refrain from scratching despite intense pruritus, while others
wear gloves, apply ice or cold water to the affected areas, or adopt
other various strategies to cope with the pruritus and hamper the
urge to scratch.5 In some cases, such as in hydroxyethyl starch-
induced pruritus, scratching enhances the itch sensations and
thus patients avoid to scratch and usually do not develop scratching
lesions. On the other hand, patients with an automatic scratching
behavior may present with extensive lesions in spite of an absence
Fig. 3. Scratch lesions. Pruritus of different origins may lead to scratch lesions. Two
examples of chronic pruritus patients with scratching lesions are seen. A: a patient
with atopic dermatitis exhibits excoriations; B: prurigo nodularis can be seen in a
patient with diabetogenic pruritus.
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behavior or lesions should therefore be cautiously interpreted as it
is more suitable for monitoring the progress of the pruritic condi-
tion rather than assessing its severity.5Instruments for assessing the course of pruritus
Several instruments that monitor the course of itch have been
developed by researchers. The Dynamic Pruritus Score (DPS) is a
practical tool that can be utilized for follow-up visits of patients
with chronic pruritus. Patients are asked to rate their current level
of pruritus in comparison to during their previous visit. This in-
strument could be recently validated, showing high reliability and
validity.13 While monodimensional scales as the VAS or NRS assessitch intensity at one speciﬁc point in time, the DPS provides in-
formation on the direction of the itch development, i.e. whether it
is getting better or worse with treatment.
Another option is the multidimensional 5-D itching scale, which
was designed to evaluate several components of chronic pruritus,
including the affected areas of the body, itch intensity, course of
itch through the day, disability induced by the pruritus and
whether or not the symptom has changed in the past few weeks,
and if so, how (5-D's: degree, duration, direction, disability and
distribution).14 Alternatively, the Itch-Free Days (IFD) questionnaire
is both simple and useful for observing improvements during
treatment. This questionnaire was recently validated and will be
available soon. It is composed of a set of questions, which describe
several parameters related to the itch course. A score calculation
enables a comparison of different time-points of assessment.
Other additional instruments, such as the pruritus-speciﬁc Pa-
tient Beneﬁt Index (PBI-P), have been developed to determine the
beneﬁts gained from treatment and the degree of global satisfac-
tion.15 This questionnaire assesses the relevance of 27 possible
therapeutic beneﬁts for the patient prior to treatment and the
extent to which they were met post-treatment. A weighted score is
then determined based on the therapeutic beneﬁts relevant to the
individual patient. Furthermore, the PBI-P has been validated for
chronic pruritus patients and has proven a high correlation with
scores from the VAS and Dermatological Life Quality Index (DLQI).16
In recent years, there has been an increasing interest in modern
technologies as instruments for monitoring pruritus. A patient-
oriented, mobile software application for Android, ItchApp®, was
recently developed and validated for use as a computerized diary. It
can be utilized by patients to store self-reported data regarding the
course of their itch. The app was developed with a user-friendly
design in mind and is consequently viewed as a helpful tool for
both the clinical trials and the clinical monitorship of chronic
pruritus patients.17
Psychiatric comorbidities
Psychiatric comorbidities such as anxiety and depression often
accompany chronic pruritus, particularly in patients with long-
standing symptoms and unresponsive to treatment. It is crucial to
address this issue in order to extensively assess pruritus patients.
The Hospital Anxiety and Depression Scale (HADS) is the most
widely used instrument and is comprised of two scales that analyze
anxiety and depression. It can also conveniently be used to observe
the development of these aspects over time. A high score in either
scale signals a possible pathological ﬁnding to the attending clini-
cian, who consequently discusses the possibility of a concomitant
psychiatric treatment with the patient.18,19 The Beck Depression
Inventory (BDI)20,21 and the Hamilton Rating Scale for Depression
(HRSD)22 are other valuable tools that can be used to screen for
depression in patients with somatic disorders.
Quality of life
Chronic pruritus can greatly reduce patient quality of life.23 For
this reason, there are a variety of tools available that assess the
quality of life of affected patients. The ItchyQol was developed
speciﬁcally for pruritic conditions and focuses not only on the
impact of pruritus on daily activities, but also on the characteristics
of the symptoms and on the level of psychological strain.24,25 The
DLQI constitutes an alternative instrument for both pruritus (in the
context of dermatoses or severe scratch lesions) and other
dermatological conditions.26 The DLQI is widely used and has
already been validated. Furthermore, its usefulness has been
established for patients with pruritic conditions of cutaneous
M.P. Pereira, S. St€ander / Allergology International 66 (2017) 3e76origins; however, unlike the ItchyQol, it may not be suitable for use
for patients with pruritus of normal appearing skin. The DLQI does
not address psychiatric comorbidities and should thus be com-
plemented by other tools.16 Other generic questionnaires such as
the 36-item short form (SF-36) may also be used to measure the
effect of chronic pruritus on patient quality of life.27 The SF-36,
which is also used for other conditions, focuses on key aspects
such as limitations in physical and social activities, bodily pain,
mental health, limitations due to emotional impairment, fatigue
and health perception. A short-form of this questionnaire has also
been developed.27
Interestingly, the impact on quality of life correlates with the
intensity of itch, but is not inﬂuenced by the underlying cause of
pruritus or by visible scratch lesions.28
Assessment of chronic pruritus in the clinical setting
The multifactorial nature of chronic pruritus contributes to its
refractoriness and need for comprehensive diagnostic procedures
and lengthy therapies. A detailed medical history and individual-
ized diagnostic procedures and approaches to treatment are thus
required. It is important to treat visible scratch lesions and
accompanying disorders, including psychiatric comorbidities and
sleep disorders, in addition to the itch itself. In order to adequately
manage chronic itch, it is necessary to adopt a multidisciplinary
approach to treatment.29,30
A detailed medical history and individualized diagnostic pro-
cedures and approaches to treatment are required due to the
complex multifactorial nature of chronic pruritus. Standardized
questionnaires provide attending physicians with the opportunity
to gain valuable information during each visit. Although no inter-
national standardized questionnaire has been developed yet, a few
options such as the American31 or German Itch Questionnaire
(“AGP-Questionnaire”), the Eppendorf Itch Questionnaire and the
Münster Neuroderm Questionnaire, are currently available.32,33
These questionnaires provide various information on the pruritic
disease, for instance regarding the intensity, quality and location of
pruritus, the duration of the disease and alleviating and aggravating
factors.
At each visit to the doctor's ofﬁce, patients may be asked to
complete questionnaires on various topics, including the charac-
teristics of the itch, psychiatric comorbidities (e.g. HADS), itch in-
tensity (e.g. NRS or VAS), impairment of the quality of life (e.g.
DLQI) and beneﬁts achieved by treatment from the patients' point
of view (PBI-P).34 The ﬁrst questionnaire on the characteristics of
itch should only be completed during the initial visit, while the
subsequent questionnaires serve as convenient follow-up tools. The
attending physician can thus quickly obtain the relevant informa-
tion, determine any new developments in these parameters during
follow-up visits and examine how they have been inﬂuenced by the
therapies. A European network of itch experts reached an agree-
ment that pruritus intensity and impact on quality of life are the
most relevant parameters to assess in the clinical care.35 The need
for a detailed andmethodical, physician-obtained, pruritus-speciﬁc
medical history is another essential aspect to consider. The affected
locations, comorbidities, co-medications and alleviating measures
should be documented during the initial visit. Previous therapeutic
attempts and their side effects, current medications and comor-
bidities should also be assessed.34
Chronic pruritus presents a therapeutic challenge due to its
complexity and multidisciplinary nature. Management of the
symptom can be difﬁcult in a general practice or a dermatological
ofﬁce. Centers specializing in pruritus are thus vital in providing
specialist and multifactorial treatment. Many also offer inpatient
care to patients, as well as extensive diagnostics (e.g. imagiology toexclude a neoplastic cause, food intolerance tests) and acute
treatment with off-label substances (e.g. aprepitant, a neurokinin-1
receptor antagonist) or intravenous drugs (e.g. naloxone for
cholestatic pruritus).34
Assessment of chronic pruritus in clinical trials
It is recommended to include patient-reported outcomes in
RCTs in order to demonstrate the therapeutic success from the
patient's point of view.5 Therapeutic beneﬁts, overall satisfaction
and the impairment of quality of life are associated parameters that
are important to assess. These aspects can be assessed as single-
point (e.g. symptom intensity; NRS) or two-point (e.g. DPS)
assessment during the trial (e.g. before and after treatment).
Global initiatives such as the special interest group “Scoring itch
in clinical trials” of the IFSI or the “Task Force Pruritus”, a network
of experts of the European Academy of Dermatology and Venere-
ology (EADV), are currently focused on reaching an international
consensus regarding outcome proposals for RCTs. Monodimen-
sional scales that evaluate pruritus intensity are the most widely
adopted outcome tools (e.g. the VAS or NRS). These scales, however,
produce subjective data that may reﬂect satisfaction rather than
the itch intensity. Physicians are therefore urged to explain the
purpose of the scale, as well as perform a test run, prior to begin-
ning the study. There are also methodological aspects to consider. A
consensus regarding the frequency with which this outcome
should be assessed throughout a RCT (daily journal or only during
study visits) or per day (once per day or several times per day) has
yet to be reached. The outcomes themselves may vary between
RCTs and depending on the study. Some studies focus on the mean
itch intensity, while others concentrate on the most intense itch as
the primary outcome.
The IFSI recommends that RCTs also include, in addition to data
taken from the VAS, additional patient-reported outcomes such as
those regarding quality of life, resulting psychiatric comorbidities
and sleep disorders.
Outcomes on the course of the symptom may provide more
sensitive data compared to static scales assessing symptom in-
tensity.36 Therefore newly developed tools evaluating the course of
the pruritus may be in foreground in future RCTs. Monitoring in-
struments (e.g. the DPS, IFD) are still infrequently used in RCTs and
require swift validation. Evaluating the beneﬁts from treatment
from the patients' point of view provides indispensable informa-
tion. The PBI should thus be implemented for use in RCTs. Scales
that examine psychiatric comorbidities (e.g. the HADS and BDI) also
function as a screening tool for unsuitable study patients and
contribute with vital information on study participants' well-being
during RCTs. Scales developed for determining sleep impairment
(e.g. the Stanford and Epworth Sleepiness Scales and the Athens
Insomnia Scale) may also be adopted for use in providing sup-
porting information. Other scales are important for the insight they
provide through determining the impact on patients' quality of life.
Although the ItchyQol comprises a valid alternative, the DLQI re-
mains the most widely used tool.5
A general agreement of international medical communities on
which instruments are best suited for use in RCTs on chronic pruritus
wouldallow forcomparisonsbetween studiesandensure thehighest
medical and professional standards. The IFSI (www.itchforum.org)
and EADV (http://www.eadv.org/scientiﬁc/task-forces/) created a
platform, which enables a discussion of these issues.
Conclusion
Chronic pruritus is a complex condition characterized by a
multifactorial nature. It is thus necessary to adopt a standardized
M.P. Pereira, S. St€ander / Allergology International 66 (2017) 3e7 7approach for the management of affected patients. Scales utilized
to measure itch intensity are frequently used in clinical practice;
however, additional instruments assessing the itch intensity, psy-
chiatric comorbidities, impact on patient quality of life and patient
satisfaction should also be integrated into the routine care of
chronic pruritus. A consensus on which instruments to use for as-
sessments in RCTs should be reached in order to ensure the highest
standards.
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